A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.